SCHEMBL23874992

SCHEMBL23874992

COC(=O)c1cc(-c2ccccn2)ccc1O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 1/20 0.58
CA12 O43570 1/20 0.51
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
CA7 P43166 1/20 0.51
CA9 Q16790 1/20 0.51
CA14 Q9ULX7 1/20 0.51
LMNA P02545 1/20 0.50
TSHR P16473 1/20 0.50
GABRG2 P18507 1/20 0.49
GABRB3 P28472 1/20 0.49
GABRA3 P34903 1/20 0.49
KDM4E B2RXH2 1/20 0.49
TGFBR1 P36897 1/20 0.46
EGFR P00533 1/20 0.45
NOX4 Q9NPH5 1/20 0.45
GRM5 P41594 2/20 0.45
P2RX7 Q99572 1/20 0.44
ERN1 O75460 2/20 0.44
KAT6A Q92794 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31480191 0.89 AXL (0.58) AXLCA12CA1CA2CA7
SCHEMBL30930601 0.88 AXL (0.61) AXLGABRG2GABRB3GABRA3KDM4E
SCHEMBL27284650 0.88 AXL (0.61) AXLGABRG2GABRB3GABRA3KDM4E
SCHEMBL1788339 0.84 P2RX7 (0.58) AXLLMNAGABRG2GABRB3GABRA3
SCHEMBL30930680 0.83 AXL (0.58) AXLGABRG2GABRB3GABRA3KDM4E
SCHEMBL27284549 0.83 AXL (0.58) AXLGABRG2GABRB3GABRA3KDM4E
SCHEMBL10959096 0.82 MCL1 (0.62) KDM4EDHODH
SCHEMBL30614608 0.82 MCL1 (0.62) KDM4EDHODH
SCHEMBL5929024 0.82 AXL (0.57) AXLGABRG2GABRB3GABRA3KDM4E
SCHEMBL205611 0.82 AXL (0.57) AXLLMNAGABRG2GABRB3GABRA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210371403-A1 SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS JNANA THERAPEUTICS INC. 2021-12-02 US disclosed
US-20210299070-A1 METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY JNANA THERAPEUTICS INC. 2021-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210299070-A1 METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY SLC19A1, SLC1A5, SLC1A2 AXL 4878/4885CA12 3013/4885CA1 2338/4885
US-20210371403-A1 SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS SNRPE, G3BP1, G3BP2 AXL 4692/4885CA12 4649/4885CA1 4586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.